DarioHealth (NASDAQ:DRIO) Shares Cross Below 200-Day Moving Average of $6.02

DarioHealth Corp. (NASDAQ:DRIOGet Rating) crossed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $6.02 and traded as low as $4.08. DarioHealth shares last traded at $4.22, with a volume of 154,609 shares.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on the company. Aegis decreased their price target on DarioHealth from $20.00 to $15.00 and set a “buy” rating for the company in a report on Thursday, August 18th. Cowen decreased their price target on DarioHealth from $18.00 to $14.00 and set an “outperform” rating for the company in a report on Tuesday, August 16th. Cowen decreased their price target on DarioHealth from $18.00 to $14.00 and set an “outperform” rating for the company in a report on Tuesday, August 16th. Finally, Alliance Global Partners upgraded DarioHealth from a “neutral” rating to a “buy” rating and set a $8.75 price target for the company in a report on Friday, May 13th.

DarioHealth Stock Performance

The company has a market capitalization of $96.97 million, a PE ratio of -1.13 and a beta of 1.27. The company has a debt-to-equity ratio of 0.23, a quick ratio of 5.71 and a current ratio of 6.35. The company has a 50 day moving average price of $5.75 and a 200 day moving average price of $6.02.

DarioHealth (NASDAQ:DRIOGet Rating) last posted its quarterly earnings results on Monday, August 15th. The company reported ($0.74) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.77) by $0.03. The business had revenue of $6.18 million for the quarter, compared to analyst estimates of $8.27 million. DarioHealth had a negative return on equity of 77.24% and a negative net margin of 301.07%. During the same period in the prior year, the company posted ($0.99) EPS. Equities analysts forecast that DarioHealth Corp. will post -3.72 EPS for the current year.

Institutional Investors Weigh In On DarioHealth

Several institutional investors and hedge funds have recently made changes to their positions in DRIO. Clal Insurance Enterprises Holdings Ltd acquired a new stake in shares of DarioHealth during the 1st quarter valued at approximately $9,357,000. Phoenix Holdings Ltd. increased its position in DarioHealth by 391.3% in the first quarter. Phoenix Holdings Ltd. now owns 1,341,027 shares of the company’s stock worth $7,832,000 after buying an additional 1,068,092 shares during the period. Millennium Management LLC increased its position in DarioHealth by 729.9% in the second quarter. Millennium Management LLC now owns 488,772 shares of the company’s stock worth $3,001,000 after buying an additional 429,880 shares during the period. MAI Capital Management acquired a new stake in DarioHealth in the second quarter worth $2,140,000. Finally, Nantahala Capital Management LLC increased its position in DarioHealth by 21.6% in the first quarter. Nantahala Capital Management LLC now owns 1,716,007 shares of the company’s stock worth $10,021,000 after buying an additional 304,326 shares during the period. 46.50% of the stock is owned by institutional investors and hedge funds.

DarioHealth Company Profile

(Get Rating)

DarioHealth Corp. operates as a digital therapeutics company in the United States, Canada, the European Union, Australia, and New Zealand. The company offers Dario's metabolic solutions to address metabolic health needs, such as diabetes, hypertension, and weight management; Dario Musculoskeletal, which helps to prevent and treat the most common MSK conditions; Dario's behavioral health solution that optimizes access to evidence-based care; chronic condition management solutions; DarioEngage, a proprietary care management platform; and device-specific disposables test strip cartridges, lancets, and blood glucose monitoring systems.

Further Reading

Receive News & Ratings for DarioHealth Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DarioHealth and related companies with MarketBeat.com's FREE daily email newsletter.